Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling | Zendy

Martina I. Klein | Zendy; Ralph T. Schermuly | Zendy; Peter Ellinghaus | Zendy; Hendrik Milting | Zendy; Bernd Riedl | Zendy; Sevdaliikolova | Zendy; Soni Savai Pullamsetti | Zendy; Norbert Weißmann | Zendy; Eva Dony | Zendy; Rajkumar Savai | Zendy; Hossein A. Ghofrani | Zendy; Friedrich Grimminger | Zendy; Andreas Büsch | Zendy; Stefan Schäfer | Zendy

Open Access

Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

Author(s) -

Martina I. Klein,

Ralph T. Schermuly,

Peter Ellinghaus,

Hendrik Milting,

Bernd Riedl,

Sevdaliikolova,

Soni Savai Pullamsetti,

Norbert Weißmann,

Eva Dony,

Rajkumar Savai,

Hossein A. Ghofrani,

Friedrich Grimminger,

Andreas Büsch,

Stefan Schäfer

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.779751

Subject(s) - sorafenib , medicine , pulmonary hypertension , imatinib , tyrosine kinase , tyrosine kinase inhibitor , kinase , pharmacology , cardiology , endocrinology , receptor , chemistry , biochemistry , cancer , myeloid leukemia , hepatocellular carcinoma

Inhibition of tyrosine kinases, including platelet-derived growth factor receptor, can reduce pulmonary arterial pressure in experimental and clinical pulmonary hypertension. We hypothesized that inhibition of the serine/threonine kinases Raf-1 (also termed c-Raf) and b-Raf in addition to inhibition of tyrosine kinases effectively controls pulmonary vascular and right heart remodeling in pulmonary hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research